| 肝动脉灌注化疗在肝癌转化治疗中的作用 |
| |
| 引用本文： | 徐立,陈敏山,胡自力.肝动脉灌注化疗在肝癌转化治疗中的作用[J].中国实用外科杂志,2021,41(3):272-275. |
| |
| 作者姓名： | 徐立 陈敏山 胡自力 |
| |
| 作者单位： | 中山大学肿瘤防治中心肝脏外科 华南肿瘤学国家重点实验室 肿瘤协同创新中心，广东广州510060 |
| |
| 基金项目： | 国家科技重大专项(No.2018ZX10723204,No.2018ZX10302205)。 |
| |
| 摘 要： | 根治性切除是肝癌病人得以长期生存的主要治疗手段,然而我国肝癌诊断时大部分为中晚期,可行根治性切除者＜30％.众多学者尝试利用多种方式对初始不可切除肝癌进行转化治疗,力争缩小肿瘤或使肝癌降期,以创造更多手术切除机会.近年来,奥沙利铂/亚叶酸钙/5-氟尿嘧啶(FOLFOX)方案肝动脉灌注化疗在不可切除肝癌病人中呈现出明显优...
|
| 关 键 词： | 肝细胞癌 肝动脉灌注化疗 转化治疗 |
The role of hepatic arterial infusion chemotherapy in conversion therapy for hepatocellular carcinoma |
| |
| XU Li,CHEN Min-shan,HU Zi-li.The role of hepatic arterial infusion chemotherapy in conversion therapy for hepatocellular carcinoma[J].Chinese Journal of Practical Surgery,2021,41(3):272-275. |
| |
| Authors: | XU Li CHEN Min-shan HU Zi-li |
| |
| Institution: | (Department of Liver Surgery,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in Southern China,Collaborative Innovation Center for Cancer Medicine,Guangzhou 510060,China) |
| |
| Abstract: | Radical resection is the main treatment for patients with hepatocellular carcinoma(HCC)who got long term survival. However Chinese patients with HCC are often diagnosed at intermediate-advanced stage,and less than 30%of them could receive radical resection. Numerous efforts have been made to shrink or down-staging HCC in order to create the chances for radical resection. In recent years,hepatic arterial infusion chemotherapy(HAIC)with oxaliplatin/CF/5-FU(FOLFOX regimen)has showed significant superiority in tumor response rate and safety,and created better chances for radical resection of HCC as a conversion therapy. Combined treatments with FOLFOX-HAIC play more and more important roles in HCC therapy. |
| |
| Keywords: | hepatocellular carcinoma hepatic arterial infusion chemotherapy conversion therapy |
| 本文献已被 CNKI 维普 等数据库收录！ |
| 点击此处可从《中国实用外科杂志》浏览原始摘要信息 |
| 点击此处可从《中国实用外科杂志》下载免费的PDF全文 |
